PHARMANOVIA
PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918003077/en/
James Burt, CEO, Pharmanovia (Photo: Business Wire)
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi.
The brands span four therapy areas of ongoing unmet need associated with CNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic.
Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.1 The acquired brands include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® may also be used as adjunctive therapy in epilepsy.1
Phenobarbital (brand: Gardenal®*) is used as an anti-convulsant to treat all forms of epilepsy except absence seizures.2
Cyamemazine (brand: Tercian®*†) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant.3
Prochlorperazine (brand: Stemetil®*) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety.4,5
Dr James Burt, Pharmanovia CEO, commented: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium® and Gardenal®, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.”
“Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.”
-Ends-
Notes to editors
*Not all indications are approved in every market. For local indications it is advised to check the local approved label. †Tercian® is only available in France.
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
For more information about Pharmanovia, please visit www.pharmanovia.com
About Sanofi
Sanofi is an innovative global healthcare company, driven by one purpose: to chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
References
1 - Frisium Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/1574 – last accessed 11.9.2023
2 - Phenobarbital Sodium Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3604/smpc#gref - last accessed 11.9.2023
3 - Terican Summary of Product Characteristics, https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66615713&typedoc=R – last accessed 11.9.2023
4 - Stemetil Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3735/smpc#about-medicine - last accessed 11.9.2023
5 - Stemetil Tablets Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/99/smpc#about-medicine - last accessed 11.9.2023
COR2023PR00207 – Date of Preparation – 14.9.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918003077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release
Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 14:12:00 CET | Press release
Digital payments veteran Rachelle Alexis Lim now spearheads MultiSafepay’s operational strategy as it brings its innovative omnichannel payment platform to businesses of all sizes across Europe, driving inclusive growth for SMEs. Founder, Olaf Geurs, who has led MultiSafepay for nearly three decades will remain Chief Technology Officer and hold his position on the board of directors. In this role he will remain instrumental to driving innovation. Since the start of its strategic partnership with global payment and digitisation provider Antom, MultiSafepay's transaction volume has nearly doubled, and its merchant base has increased by over a quarter. MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie7.11.2025 13:30:00 CET | Press release
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging effortsPositions Organon for future investment in growth opportunities with a focus on women’s health biopharma and other strategic prioritiesLaborie’s capabilities in medical technology will facilitate broader access to JADA for more mothers Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transf
ADNOC Partners With Comera Financial Holdings to Empower Its UAE Suppliers and SMEs With Smart Financing Solutions7.11.2025 13:23:00 CET | Press release
Strategic partnership unlocks quick access to purchase order financing through an automated platformInitiative to enhance SME cash flow, strengthen supply chain resilience, and support UAE economic diversification ADNOC has signed a strategic partnership with Comera Financial Holdings to enhance financial access for ADNOC’s UAE-based small and medium enterprises (SMEs) and suppliers. The collaboration will launch a financing program, enabling SMEs and suppliers to access working capital more efficiently to enable them to more swiftly deliver on ADNOC purchase orders (PO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107458886/en/ ADNOC Partners with Comera Financial Holdings to Empower its UAE Suppliers and SMEs with Smart Financing Solutions (Photo: AETOSWire) The initiative will boost access to liquidity while enabling scalable operations and sustainable growth for the suppliers and SMEs. The partnership reinforces AD
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom